Tubeimoside I
Based on 5 publication(s) in Google Scholar
Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases.
For research use only. We do not sell to patients.
- Purity : 99.96%
- CAS No.: 102040-03-9
- Formula: C63H98O29
- Molecular Weight:1319.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Tubeimoside I
More-
Cell Proliferation/Viability Assay
-
Flow Cytometry
-
WB
-
IF
-
In Vivo Efficacy Study
All VEGFR Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
12.3 μM
Compound: TBM I
|
Antiproliferative activity against human A549 cells after 72 hrs by MTS assay
Antiproliferative activity against human A549 cells after 72 hrs by MTS assay
|
[PMID: 30439592] |
| DU-145 | IC50 |
10 μM
Compound: TBM I
|
Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay
Antiproliferative activity against human DU145 cells after 24 hrs by MTT assay
|
[PMID: 30439592] |
| HeLa | IC50 |
17.1 μM
Compound: TBM I
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 30439592] |
| HeLa | IC50 |
25 μM
Compound: TBM I
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 30439592] |
| HeLa | IC50 |
27.1 μM
Compound: TBM I
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 30439592] |
| HeLa | IC50 |
34.8 μM
Compound: TBM I
|
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay
|
[PMID: 30439592] |
| HepG2 | IC50 |
15.5 μM
Compound: TBM I
|
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 30439592] |
| HUVEC | IC50 |
17.9 μM
Compound: TBM I
|
Antiproliferative activity against HUVEC after 72 hrs
Antiproliferative activity against HUVEC after 72 hrs
|
[PMID: 30439592] |
| HUVEC | IC50 |
21.4 μM
Compound: TBM I
|
Antiproliferative activity against HUVEC after 48 hrs
Antiproliferative activity against HUVEC after 48 hrs
|
[PMID: 30439592] |
| HUVEC | IC50 |
24.2 μM
Compound: TBM I
|
Antiproliferative activity against HUVEC after 24 hrs
Antiproliferative activity against HUVEC after 24 hrs
|
[PMID: 30439592] |
| JEG-3 | IC50 |
8.5 μM
Compound: TBM I
|
Antiproliferative activity against human JEG3 cells after 24 hrs by MTT assay
Antiproliferative activity against human JEG3 cells after 24 hrs by MTT assay
|
[PMID: 30439592] |
| NCI-H1299 | IC50 |
10 μM
Compound: TBM I
|
Antiproliferative activity against human NCI-H1299 cells after 48 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1299 cells after 48 hrs by CCK-8 assay
|
[PMID: 30439592] |
| NCI-H460 | IC50 |
20 μM
Compound: TBM I
|
Antiproliferative activity against human NCI-H460 cells after 9 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells after 9 hrs by MTT assay
|
[PMID: 30439592] |
| NCI-H460 | IC50 |
23.3 μM
Compound: TBM I
|
Antiproliferative activity against human NCI-H460 cells after 24 hrs by WST-1 assay
Antiproliferative activity against human NCI-H460 cells after 24 hrs by WST-1 assay
|
[PMID: 30439592] |
| PC-3 | IC50 |
20 μM
Compound: TBM I
|
Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay
|
[PMID: 30439592] |
| PC-9 | IC50 |
10.2 μM
Compound: TBM I
|
Antiproliferative activity against human PC9 cells after 72 hrs by MTS assay
Antiproliferative activity against human PC9 cells after 72 hrs by MTS assay
|
[PMID: 30439592] |
| SK-OV-3 | IC50 |
16 μM
Compound: TBM I
|
Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay
Antiproliferative activity against human SKOV3 cells after 24 hrs by MTT assay
|
[PMID: 30439592] |
| T-24 | IC50 |
20 μM
Compound: TBM I
|
Antiproliferative activity against human T24 cells after 24 hrs by MTT assay
Antiproliferative activity against human T24 cells after 24 hrs by MTT assay
|
[PMID: 30439592] |
In Vitro
Tubeimoside I (0.5-8 µM; 6-48 h) induces cytoprotective autophagy in human breast cancer cells (MDA-MB-231, MCF-7, T47D) via Akt-mediated pathway[1].
Tubeimoside I (20 µM; 24 h) inhibits the late stage of autophagic flux in lung cancer cells transfected with mCherry-GFP-LC3 tandem plasmids[2].
Tubeimoside I (0-30 µM; 24 h) markedly decreases cervical cancer (Hela and SiHa) cell viability in a dose-dependent manner[3].
Tubeimoside I (25 μM; 4-24 h) causes cell cycle arrest at the G2/M phase in HeLa cells in a dose- and time- dependent manner[4].
Tubeimoside I (3-15 μM; 12-24 h) induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells DU145 and PC3[5].
Tubeimoside I (15-30 μM; 24 h) induces apoptosis in HepG2 and L-02 cells[6].
Tubeimoside I (2-6 μM; 1 h) attenuates LPS-induced inflammation in RAW 264.7 cells, inhibiting the production of pro-inflammatory cytokines TNF-α, IL-6 and IL-1β[7].
Tubeimoside I (0.5-10 μM; 48 h) inhibits the viability of HCT-116 colon cancer cells in a dose-dependent manner[10].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7, MDA-MB-231, T47D
-
Concentration:0.5 μM, 1 μM, 2 μM, 4 μM, 8 μM
-
Incubation Time:6, 9, 12, 24, 36 h
-
Result:Induced apoptosis in a dose-dependent manner, as determined by increased cleaved PARP and caspase-3 levels.
Decreased the levels of Mcl-1, Bcl-xl, and Bcl-2 in a time- and dose- dependent manner.
In Vivo
Tubeimoside I (3 mg/kg; i.p.; daily; 16 days) inhibits the growth of HeLa-xenografted tumors in nude mice, as indicated by smaller tumor size, volume, and mass[3].
Tubeimoside I (1-4 mg/kg; i.p.; 1 h before LPS challenge) reduces lung injury, down-regulates the secretion of TNF-α, IL-6 and IL-1β, and inhibits the activation of NF-κB and MAPK in a murine model of LPS-induced acute lung injury[7].
Tubeimoside I (45-180 mg/kg; p.o.; daily; 21 consecutive days) attenuates inflammation and oxidative damage in a mice model of PM2.5‑induced pulmonary injury[8].
Tubeimoside I (4 mg/kg; i.p.; 1 h before cecal ligation and puncture (CLP)) improves survival of mice in sepsis by inhibiting inducible nitric oxide synthase expression[9].
Tubeimoside I (4 mg/kg; i.p.; every day; 28 days) improves recovery from hindlimb ischemia and increases capillary density in C57BL/6 mice[11].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5-week-old male BALB/c nude mice (weighing 18-22 g), lung cancer xenograft model established by subcutaneous injection of NCI-H1299 cells[2]
-
Dosage:1 mg/kg, 4 mg/kg
-
Administration:Intraperitoneal injection, 13 days
-
Result:Reduced the tumor volume and weight.
Significantly upregulated the expression levels of cleaved-PARP, cleaved-caspase 3, LC3-II, and p62 in the tumor tissues.
-
Animal Model:Female BALB/c nude mice (4-week-old) with HeLa cell xenograft model[3]
-
Dosage:3 mg/kg
-
Administration:Intraperitoneal injection, daily, for 16 days
-
Result:Decreased the expression of Ki67 in tumor tissues, indicating reduced proliferating ability.
Induced tumor cell apoptosis, as evidenced by the accumulation of cleaved-CASP3 and cleaved-PARP1 in tumor tissues.
Induced autophagosome accumulation in tumor cells, with increased LC3 II expression and enhanced LC3 staining in tumor tissues.
Chemical Information
-
CAS No. 102040-03-9
-
Appearance Solid
-
Molecular Weight 1319.43
-
Formula C63H98O29
-
Color White to off-white
-
SMILES
C[C@@]12C([C@@]3([H])[C@](C(O[C@@H]4OC[C@H](O)[C@H](O)[C@H]4O[C@@H]5O[C@@H](C)[C@H](OC(C[C@](O)(C)CC6=O)=O)[C@@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]5O)=O)(CCC(C)(C)C3)CC2)=CC[C@@]8([H])[C@@]1(C)CC[C@]([C@](C)(CO)[C@H]9O[C@@H]%10O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%10O[C@@H]%11OC[C@H](O6)[C@H](O)[C@H]%11O)([H])[C@]8(C)C[C@@H]9O
-
Synonyms
Tubeimoside-1; Lobatoside-H
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Pharmacol Res
Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]2020 May:155:104751. PMID: 32151678 -
Phytomedicine
Tubeimoside Ⅰ targets sodium/potassium ATPase alpha 1 subunit to selectively eliminate senescent cells and alleviate aging-associated abnormalities. [Abstract]2026 Jul:156:158202. PMID: 42035526 -
Transl Oncol
Tubeimoside I induces mitophagy by activating the PINK1/Parkin/Mfn2 signaling pathway in acute myeloid leukemia cells. [Abstract]2025 May:55:102355. PMID: 40112502
Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]
Cell viability was assessed after PBS and TBMS1 (Tubeimoside I) treatment for 24 and 48 hours.
Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]
Annexin V-PI flow cytometry analysis of apoptosis in AML cells treated with TBMS1 (Tubeimoside I) for 24 hours.
Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]
TBMS1 (Tubeimoside I) induces mitophagy in AML cells. The expression of autophagy-related proteins was detected by Western blot.
Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]
TBMS1 (Tubeimoside I) induces mitophagy in AML cells. LC3B protein expression was detected by confocal microscopy.
Tubeimoside I purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 May:55:102355. [Abstract]
Tumor weight and volume after 21 days of treatment with saline and TBMS1 (Tubeimoside I: 5 mg/kg).
-
Biochem Biophys Res Commun
Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads. [Abstract]2025 Aug 30:776:152184. PMID: 40517671 -
Oxid Med Cell Longev
2023 Jan 14:2023:9966355. PMID: 36691640
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (37.90 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (1.89 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
-
Data Sheet (298 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jiang SL, et al. Tubeimoside-1, a triterpenoid saponin, induces cytoprotective autophagy in human breast cancer cells in vitro via Akt-mediated pathway. Acta Pharmacol Sin. 2019 Jul;40(7):919-928. [Content Brief]
[2]. Wang K, et al. Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria. Cell Death Dis. 2020 Aug 26;11(8):708. [Content Brief]
[3]. Feng X, et al. Tubeimoside I induces accumulation of impaired autophagolysosome against cervical cancer cells by both initiating autophagy and inhibiting lysosomal function. Cell Death Dis. 2018 Nov 2;9(11):1117. [Content Brief]
[4]. Xu Y, et al. Multiple pathways were involved in tubeimoside-1-induced cytotoxicity of HeLa cells. J Proteomics. 2011 Dec 21;75(2):491-501. [Content Brief]
[5]. Yang JB, et al. Tubeimoside-1 induces oxidative stress-mediated apoptosis and G0/G1 phase arrest in human prostate carcinoma cells in vitro. Acta Pharmacol Sin. 2016 Jul;37(7):950-62. [Content Brief]
[6]. Wang Y, et al. Natural plant extract tubeimoside I promotes apoptosis-mediated cell death in cultured human hepatoma (HepG2) cells. Biol Pharm Bull. 2011;34(6):831-8. [Content Brief]
[7]. Wu Q, et al. Tubeimoside-1 attenuates LPS-induced inflammation in RAW 264.7 macrophages and mouse models. Immunopharmacol Immunotoxicol. 2013 Aug;35(4):514-23. [Content Brief]
[8]. Zhang JB, et al. Tubeimoside I attenuates inflammation and oxidative damage in a mice model of PM2.5-induced pulmonary injury. Exp Ther Med. 2018 Feb;15(2):1602-1607. [Content Brief]
[9]. Luo M, et al.Tubeimoside I improves survival of mice in sepsis by inhibiting inducible nitric oxide synthase expression. Biomed Pharmacother. 2020 Jun;126:110083. [Content Brief]
[10]. Wu T, et al. Tubeimoside-I, an inhibitor of HSPD1, enhances cytotoxicity of oxaliplatin by activating ER stress and MAPK signaling pathways in colorectal cancer. J Ethnopharmacol. 2025 Jan 10;336:118754. [Content Brief]
[11]. Yang X, et al. Tubeimoside I promotes angiogenesis via activation of eNOS-VEGF signaling pathway. J Ethnopharmacol. 2021 Mar 1;267:113642. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.7579 mL | 3.7895 mL | 7.5790 mL | 18.9476 mL |
| 5 mM | 0.1516 mL | 0.7579 mL | 1.5158 mL | 3.7895 mL | |
| 10 mM | 0.0758 mL | 0.3790 mL | 0.7579 mL | 1.8948 mL | |
| 15 mM | 0.0505 mL | 0.2526 mL | 0.5053 mL | 1.2632 mL | |
| 20 mM | 0.0379 mL | 0.1895 mL | 0.3790 mL | 0.9474 mL | |
| 25 mM | 0.0303 mL | 0.1516 mL | 0.3032 mL | 0.7579 mL | |
| 30 mM | 0.0253 mL | 0.1263 mL | 0.2526 mL | 0.6316 mL |